Figure 1.

Scatter plots of A, baseline change in urinary glucose excretion for 24 hours (ΔUGE_24h) vs fasting plasma glucose (FPG), B, absolute UGE_24h vs area under the concentration–time curve from time of dosing to 24 h after administration (AUC_24h) and C, ΔUGE_24h vs area under the concentration–time curve from time of dosing to 24 h after administration AUC_24h. Green circles: healthy subjects (ipragliflozin), black circles: healthy subjects (placebo), red circles: type 2 diabetes mellitus (T2DM) patients (ipragliflozin), yellow circles: T2DM patients (placebo), filled circles: patients with significantly high baseline UGE_24h (>50 g), green dotted line: locally weighted scatterplot smoothing line in healthy subjects (ipragliflozin), red dotted line: locally weighted scatterplot smoothing line in T2DM patients (ipragliflozin).